MedTrace Logo

Cycloplegic Refraction Among Children

NCT05442801 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-07-05

No results posted yet for this study

Summary

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations. This will be a prospective double-blinded randomized clinical trial (RCT), multi center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Conditions

  • Cycloplegia

Interventions

DRUG

Cyclopentolate

Well known eye drop used for cycloplegic refraction among children.

DRUG

Tropicamide

Well known eye drop used for cycloplegic refraction among children.

Sponsors & Collaborators

  • Islamic Hospital, Jordan

    lead OTHER

Principal Investigators

  • Wejdan Al-Thawabieh, MD · Ophthalmology Department, Islamic Hospital, Amman, Jordan

  • Rami Al-Omari, MD · Faculty of Medicine, Ophthalmology, Yarmouk University, Irbid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-06-01
Completion
2022-06-20

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05442801 on ClinicalTrials.gov